Home > Insider Trading > Filing (0001209191-15-066702)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
876343	Biotime Inc	BTX	Biological Products, (No Disgnostic Substances) (2836)	943127919

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1321073	Lahue Stephen Cartt	1301 Harbor Bay Parkway Alameda CA 94502		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares, No Par Value	Acquisiton	2015-08-14	18,400	$2.65	98,525	No	4	P	Direct
Common Shares, No Par Value	Acquisiton	2015-08-17	39,400	$2.83	137,925	No	4	P	Direct
Common Shares, No Par Value	Acquisiton	2015-08-18	17,200	$2.90	155,125	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Shares	Option to Purchase Common Shares	$3.57		2020-06-30	20,000	20,000	Direct
Common Shares	Option to Purchase Common Shares	$3.43		2019-11-03	20,000	20,000	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2020-06-30	20,000	20,000	Direct
2019-11-03	20,000	20,000	Direct

Footnotes

The price of $2.6498 per share represents a weighted average of prices ranging from $2.63 to $2.679 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
The price of $2.8294 per share represents a weighted average of prices ranging from $2.69 to $2.99 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
The price of $2.8972 per share represents a weighted average of prices ranging from $2.86 to $3.00 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
Will become exercisable in four equal quarterly installments after the date of grant on July 1, 2015 based upon continued service on the board of directors.
5,000 options became exercisable on December 31, 2014; March 31, 2015; and June 30, 2015. The remaining 5,000 options will become exercisable on September 30, 2015 based upon continued service on the board of directors.